BRAF and colorectal carcinoma: Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutations, human epidermal growth factor receptor 2 (HER2) (ERBB2) amplification, and neurotrophic receptor tyrosine kinase (NTRK) fusions are the actionable gene alterations in CRC patients.